Literature DB >> 20843740

Adaptation of Staphylococcus aureus to the cystic fibrosis lung.

Christiane Goerke1, Christiane Wolz.   

Abstract

Staphylococcus aureus colonizes the lungs of cystic fibrosis (CF) patients and despite treatment with antibiotics results in recurrent and relapsing infections. With increasing duration of the infection, the bacterial population is exposed more and more to changing selective pressures exerted by the host immune system, to frequent therapeutic interventions, and to interference with other microorganisms. S. aureus has evolved a variety of strategies to adapt to these challenges: Recombination and mutation provide the population with a preselected heterogeneity, resulting in an inheritable shift of phenotypic traits. This includes the emergence of isolates with mutations in metabolic (e.g. small-colony variants) and regulatory (e.g. agr mutants) genes. Additionally, phages become mobilized with a higher frequency during infection, raising the propensity for recombination. On the other hand, S. aureus can also adapt to the CF lung using regulatory mechanisms which are not well understood in this context. The quorum-sensing system agr is not activated during lung infection in CF, which is consistent with a proposed biofilm mode of growth in the lungs and also with the observation that in CF patients the organism usually remains localized in the lungs without systemic manifestation. Altogether, adaptive processes result in the generation of a heterogeneous S. aureus population in the CF lung which is highly protected against antibiotic therapy, expressing factors necessary for persistence rather than virulence.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843740     DOI: 10.1016/j.ijmm.2010.08.003

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  50 in total

1.  RNA antitoxin SprF1 binds ribosomes to attenuate translation and promote persister cell formation in Staphylococcus aureus.

Authors:  Marie-Laure Pinel-Marie; Régine Brielle; Camille Riffaud; Noëlla Germain-Amiot; Norbert Polacek; Brice Felden
Journal:  Nat Microbiol       Date:  2021-01-04       Impact factor: 17.745

Review 2.  Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.

Authors:  John Barlow
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-09       Impact factor: 2.673

3.  Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against Staphylococcus aureus isolated from the airways of cystic fibrosis patients.

Authors:  Katarzyna Garbacz; Wojciech Kamysz; Lidia Piechowicz
Journal:  Virulence       Date:  2016-07-22       Impact factor: 5.882

Review 4.  For the Greater (Bacterial) Good: Heterogeneous Expression of Energetically Costly Virulence Factors.

Authors:  Kimberly M Davis
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

5.  In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response.

Authors:  E López-Collazo; T Jurado; J de Dios Caballero; M Pérez-Vázquez; A Vindel; E Hernández-Jiménez; J Tamames; C Cubillos-Zapata; M Manrique; R Tobes; L Máiz; R Cantón; F Baquero; R Del Campo
Journal:  Mucosal Immunol       Date:  2014-08-13       Impact factor: 7.313

Review 6.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type.

Authors:  Long M G Bui; Peter Hoffmann; John D Turnidge; Peter S Zilm; Stephen P Kidd
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

8.  Artificial Selection for Pathogenicity Mutations in Staphylococcus aureus Identifies Novel Factors Relevant to Chronic Infection.

Authors:  Kathryn McLean; Elizabeth A Holmes; Kelsi Penewit; Duankun K Lee; Samantha R Hardy; Mingxin Ren; Maxwell P Krist; Kevin Huang; Adam Waalkes; Stephen J Salipante
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

9.  Cell differentiation defines acute and chronic infection cell types in Staphylococcus aureus.

Authors:  Juan-Carlos García-Betancur; Angel Goñi-Moreno; Thomas Horger; Melanie Schott; Malvika Sharan; Julian Eikmeier; Barbara Wohlmuth; Alma Zernecke; Knut Ohlsen; Christina Kuttler; Daniel Lopez
Journal:  Elife       Date:  2017-09-12       Impact factor: 8.140

Review 10.  The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response.

Authors:  Alexandra E Paharik; Alexander R Horswill
Journal:  Microbiol Spectr       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.